|1315 Capital||Pennsylvania, Philadelphia, United States|
|Access Biotechnology||New York, New York, United States|
|ALi Corporation||Taipei, Taiwan|
|B&Y Venture Capital Partners||-|
|Blue Shield Information Security Technology||-|
|Bridgescale Partners||California, Menlo Park, United States|
|Dongfeng Motor Group||China, Hubei, Wuhan|
|Mount Wilson Ventures||California, Pasadena, United States|
|Mutschler Ventures AG||Baar, Switzerland, Zug|
|RBI Opportunities Fund||-|
|Rive Private Investment||Geneva, Geneve, Switzerland|
|Shangyan Jingji Zixun||-|
|STAGE Japan||Japan, Toshima|
|Syddansk Venture||Denmark, Kolding, Syddanmark|
|Tongmeng Touzi||Beijing, China, Haidian|
|$17M||24 Mar 2022||Whitemarsh Township, Pennsylvania, United States|
|$12M||03 Mar 2021||Whitemarsh Township, Pennsylvania, United States|
|$10M||21 Feb 2019||Whitemarsh Township, Pennsylvania, United States|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.